overcam sale challeng medic deliveri nutrit beat ep
cent howev issu forc reduc revenu growth forecast
oper even though slightli rais ep guidanc sale
disrupt temporari reiter target still reduc
target remain market perform
power sale challeng strong ep
bax revenu compar street forecast
oper growth year-over-year basi renal sale fell short
street forecast medic deliveri sale came vs
consensu renal growth driven increas patient volum
periton dialysi product global double-digit pd therapi growth
 posit patient growth japan quarter launch kaguya
pharmaceut sale well ahead consensu estim
nutrit sale fell short street expect pharmaceut
strength function increas demand premix inject along
ad impact clari product continu grow doubl digit advanc
surgeri deliv sale consensu
acut therapi sale roughli line consensu forecast
sale categori total street
expect much revenu shortfal quarter came weak
medic deliveri nutrit discuss greater detail page adjust
gross margin bp ahead street forecast adjust oper
margin bp greater consensu expect bp year
year report adjust ep quarter cent ahead
street estim cent assumpt
challeng still prompt revis revenu guidanc
respect full-year revenu target constant currenc revenu growth
approxim vs previous oper growth vs prior rang
compani adjust report revenu guidanc
previous cite impact currenc gener competit cyclophosphamid
benefit acquisit clari two surgic product
impli report revenu roughli compar estim
come quarter busi segment project constant currenc
oper growth renal low-single-digit declin medic
deliveri high-single-digit growth cyclophosphamid sale
prior guidanc nutrit sale expect declin low
singl digit advanc surgeri expect increas includ tailwind
recothrom preveleak acut therapi expect increas
pleas see page report import disclosur
compani split allow baxter better focu deliv margin expans
top bottom line growth opportun longer term new baxter
hamper low singl digit top line growth trajectori lower oper
ebitda margin profil rel peer earli go clearer path forward
abl acceler top line growth better expect margin expans
opportun could bolster long-term outlook given top-lin margin profil
new baxter believ compani deserv trade premium med tech peer
current valuat keep us market perform
focus support compani
oper cash flow track grow
new tuck-in bolt-on acquisit
expect gener top-lin
gambro margin synergi deliv
improv ahead expect
om ebitda margin expans
opportun realiz sooner
pipelin opportun acquisit
contribut next five year
gambro margin synergi fail
meet key benchmark improv
om expans come
pipelin fail deliv
 fail produc new top-lin
diversifi global healthcar compani develop medic
devic product use hospit kidney dialysi center nurs home rehabilit
center clinic medic research laboratori patient in-hom use
biopharma solut also chronic acut product offer renal
divis gener total revenu medic product sale
complet acquisit gambro ab largest acquisit histori
bolster renal busi product portfolio juli spun bioscienc
divis form baxalta acquir shire
tweak part guidanc issu below-consensu guidanc
ep forecast rang bracket
street assumpt underli assumpt oper margin expans
bp annual guidanc trim slightli
prior guid due higher inventori level forecast revenu growth
approxim vs consensu expect remind compani
second-toughest oper sale growth comparison year
benefit easiest comp year bax report
revenu guidanc growth suggest total sale fall short
street forecast assum currenc tailwind compani guid
ep rang compar consensu estim
rel light guid ep function hit medic deliveri
nutrit inventori destock headwind increment fx/financi item impact
although part off-set cost save initi total anoth
cyclophosphamid factor combin neg ep hit
view medic deliveri nutrit setback address
medic deliveri sale came compar consensu
estim declin last year constant
currenc basi compani reduc full-year sale guidanc busi
result expect global sale declin low singl digit
indic product volum back desir pre-hurrican suppli level
mini-bag back mid-juli mini-bag septemb compani
work custom reinforc avail suppli call healthi
overal save one two code mini-bag howev experienc
pressur altern practic use iv push drug administr
switch competit product especi supply-constrain code
compani continu detail safeti benefit mini-bag particularli reduc
potenti medic error still recoveri path back practic chang less
straightforward challeng impos suppli constraint alon may
need sever quarter revers new protocol large-volum parenter
lvp note sale spike first five month year flu demand
amidst protract industry-wid suppli challeng led higher-than-norm
inventori level compani built sale project inventori level
unwound suppli constraint eas time said time
increment bed non-acut custom fallen short estim
howev end-us demand growth compani approxim year date
track ahead market growth roughli respect
nutrit divis sale fell short street forecast well
project sale declin overal constant currenc basi
stem weak sale fell last year lower
global sale forecast nutrit result expect sale decreas
low singl digit prior constant currenc growth assumpt
compani seen market contact estim overal result
hurricane-rel suppli constraint believ provid didnt product
adapt delay start parenter nutrit and/or reduc patient
dosag lead contract also experienc shift outsourc
nutrit compound center well competit product setback may take
multipl quarter fix manag indic alter long-term
view busi compani priorit work hospit custom
reinforc avail product recaptur sale
stand outlook lessen drama
compani guidanc chang prompt question sale ep
project manag indic yet readi provid
guidanc reiter long-term plan includ forecast
sinc forward year use price target soon think
stock absorb transitori matter guidanc especi wednesday
pullback rais ep estim cent lower
ep forecast cent revis price target
previous appli valuat multipl ep ebitda
estim respect averag result
cowen compani
chg medic good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex intang restructur non-recvr gain incom non-controlling inc inc oper ex-intang restructur non-recur gain share result mm reportedour estim cowen
cowen compani
cowen compani
year end decemb end decemb end decemb medic good gross gross net interest expens expens total expens incom incom tax incom tax incom oper ex intang restructur non-recur gain incom non-controlling intang amort inc inc oper ex-intang oper ep includ intang restructur non-recur gain share per exclud one-tim item cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
compani specif risk includ impact long-act factor viii agent
global share advat franchis limit increas plasma fraction
capac ig franchis time regulatori approv hyq line-extens
bioscienc product develop realiz synergi impact margin
gambro acquisit acquisit exposur emerg market
